Having trouble accessing articles? Reset your cache.

Aspen’s debut reveals first cell therapy investment by Domain

Why Domain made its first cell therapy investment in Aspen's autologous Parkinson’s therapy

Aspen emerged from stealth Thursday with an autologous stem cell therapy for Parkinson’s disease. The company’s 2018 $6.5 million seed round, led by Domain Associates and Axon Ventures, marked Domain’s first investment in cell therapy.

Domain became interested in Aspen Neuroscience Inc. for two main reasons, the firm's Kim Kamdar told BioCentury. The company had preclinical data showing that

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE